Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma

References

• Marchi E , O’ConnorOA. The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management. CA Cancer J. Clin.70(1), 47–70 (2020).
   PubMed Web of Science ®Google Scholar
• Zain JM . Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management. Am. J. Hematol.94(8), 929–946 (2019).
   PubMed Web of Science ®Google Scholar
• Abouyabis AN , ShenoyPJ , LechowiczMJ , FlowersCR. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk. Lymphoma49(11), 2099–2107 (2008).
   PubMed Web of Science ®Google Scholar
• Campo E , HarrisNL , JaffeESet al. In: WHO classification of tumours of haematopoietic and lymphoid tissues.SwerdlowSH ( Ed.). International Agency for Research on Cancer, Lyon, France (2008).
   Google Scholar
• Ashaye AO , BurnettH , AbogunrinS , PanchmatiaH , OvcinnikovaO , DalalM. The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review. Future Oncol.18(4), 519–535 (2022).
   PubMed Web of Science ®Google Scholar
• Laribi K , AlaniM , TruongC , Baugierde Materre A. Recent Advances in the treatment of peripheral T-Cell lymphoma. Oncologist23(9), 1039–1053 (2018).
   PubMed Web of Science ®Google Scholar
• Savage K , ChhanabhaiM , GascoyneR , ConnorsJ. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann. Oncol.15(10), 1467–1475 (2004).
   PubMed Web of Science ®Google Scholar
• Horwitz SM , AnsellS , AiWZet al. T-cell lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Cancer Netw.20(3), 285–308 (2022).
   PubMedGoogle Scholar
• Horwitz S , O’ConnorOA , ProBet al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet393(10168), 229–240 (2019).
   PubMed Web of Science ®Google Scholar
• Park SI , HorwitzSM , FossFMet al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study. Cancer125(9), 1507–1517 (2019).
   PubMed Web of Science ®Google Scholar
• Aggarwal S , KumarS , TopalogluO. Trends in hospitalization length of stay and costs in patients with peripheral T-cell lymphoma (PTCL): analysis of US national in-patient data for 2015. Value Health21(Suppl. 1), S34 (2018).
   Google Scholar
• Kruse GB , PotashmanMH , StavrakasS , WongBJ. Administration costs of intravenous chemotherapy in treating peripheral T-cell lymphoma. J. Med. Econ.17(7), 446–458 (2014).
   PubMedGoogle Scholar
• Shah A , PetrillaA , RebeiraM , FelicianoJ , LisanoJ , LeblancTW. Health care resource utilization and costs among Medicare beneficiaries newly diagnosed with peripheral T-cell lymphoma: a retrospective claims analysis. Clin. Lymphoma Myeloma Leuk.21(1), e1–e9 (2021).
   PubMed Web of Science ®Google Scholar
• Burudpakdee C , LinHM , WangWet al. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data. J. Med. Econ.19(10), 965–972 (2016).
   PubMed Web of Science ®Google Scholar
• U.S. Bureau of Labor Statistics . Measuring price change in the CPI: medical care (2023). www.bls.gov/cpi/factsheets/medical-care.htm
   Google Scholar
• Petrilla AA , ShahA , FelicianoJ , WooleryJ , LeblancTW. Burden of illness and treatment patterns among patients with peripheral T-cell lymphoma in the US healthcare setting. Curr. Med. Res. Opin.37(7), 1189–1197 (2021).
   PubMed Web of Science ®Google Scholar
• Hester L , ParkSI , LundJL. Patterns of comorbidity among older US patients with non-Hodgkin lymphoma. J. Clin. Oncol.34(Suppl. 7), 304–304 (2016).
   Web of Science ®Google Scholar
• Burke JM , LiuN , Yu-IsenbergKet al. Real-world characteristics of patients with peripheral T-cell lymphoma receiving frontline brentuximab vedotin with chemotherapy: a retrospective analysis with propensity score matching. Blood136, 18–19 (2020).
   Google Scholar
• Bachy E , BroccoliA , DeardenCet al. Controversies in the treatment of peripheral T-cell lymphoma. Hemasphere4(5), e461 (2020).
   PubMed Web of Science ®Google Scholar
• Khan M , SamaniegoF , HagemeisterFB , IyerSP. Emerging therapeutic landscape of peripheral T-cell lymphomas based on advances in biology: current status and future directions. Cancers13(22), 5627 (2021).
   PubMed Web of Science ®Google Scholar
• Iyer SP , NairR. In: Peripheral T-cell Lymphomas (PTCL).The University of Texas MD Anderson Cancer Center, TX, USA (2022). www.mdanderson.org/content/dam/mdanderson/documents/for-physicians/algorithms/cancer-treatment/ca-treatment-lymphoma-peripheral-t-cell-web-algorithm.pdf
   Google Scholar
• U.S. Food and Drug Administration . FDA approves brentuximab vedotin for previously untreated sALCL and CD30-expressing PTCL (2018). www.fda.gov/drugs/fda-approves-brentuximab-vedotin-previously-untreated-salcl-and-cd30-expressing-ptcl
   Google Scholar
• Burke JM , LiuN , YuKSet al. Retrospective analysis with propensity score matching of peripheral T-cell lymphoma treated frontline with brentuximab vedotin and chemotherapy. Oncologist28(6), 520–530 (2023).
   PubMed Web of Science ®Google Scholar
• Zhang Y , XuW , LiuH , LiJ. Therapeutic options in peripheral T cell lymphoma. J. Hematol. Oncol.9, 37 (2016).
   PubMed Web of Science ®Google Scholar
• El-Asmar J , ReljicT , AyalaEet al. Efficacy of high-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphomas as front-line consolidation or in the relapsed/refractory setting: a systematic review/meta-analysis. Biol. Blood Marrow Transplant.22(5), 802–814 (2016).
   PubMed Web of Science ®Google Scholar
• Blystad A , EnbladG , Kval⊘ySet al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant.27(7), 711–716 (2001).
   PubMed Web of Science ®Google Scholar
• Phillips E , LannonM , LopesAet al. High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK phase II study. Bone Marrow Transplant.54(3), 465–468 (2019).
   PubMed Web of Science ®Google Scholar
• Foss FM , ZinzaniPL , VoseJM , GascoyneRD , RosenST , TobinaiK. Peripheral T-cell lymphoma. Blood117(25), 6756–6767 (2011).
   PubMed Web of Science ®Google Scholar
• Bellei M , FossFM , ShustovARet al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, international T-cell project. Haematologica103(7), 1191–1197 (2018).
   PubMed Web of Science ®Google Scholar